SEC 13F Intelligence

Managers / Q2 2019 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$254M
Q2 2019
Positions
50
Filings on Record
24
2019–present window
Filed
Aug 14, 2019
original filing

Summary

Endurant Capital Management LP reported $254M in U.S.-listed holdings across 50 positions for Q2 2019.

Its largest position, Takeda Pharmaceutical, represents 6.5% of the portfolio.

Compared with Q1 2019, the fund opened 20 new positions and exited 39.

Portfolio Metrics

Turnover
+49.6%
vs prior filed quarter
Top-10 Concentration
+43.7%
share of reported value
Largest Position
+6.5%
Takeda Pharmaceutical
New / Exited
20 / 39
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 67.0%Other: 15.3%ADR: 11.8%US DOMESTIC: 5.9%
  • Common Stock · 67.0% · $170M
  • Other · 15.3% · $39M
  • ADR · 11.8% · $30M
  • US DOMESTIC · 5.9% · $15M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2019 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
PRAHPRA HEALTH SCIENCES INCNEW+97.2K97.2K+$10M$10M
HUMHUMANA INCNEW+27.8K27.8K+$7M$7M
EHCENCOMPASS HEALTH CORPNEW+114.8K114.8K+$7M$7M
SNYSANOFINEW+120.6K120.6K+$5M$5M
AZNNASTRAZENECA PLCNEW+124.9K124.9K+$5M$5M
EVOLENT HEALTH INCNEW+5.60M5.60M+$5M$5M
IOVAIOVANCE BIOTHERAPEUTICS INCNEW+173.2K173.2K+$4M$4M
NVROEURNEVRO CORPNEW+63.4K63.4K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2019

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1TAKEDA PHARMACEUTICAL CO LTDSPONSORED ADS6.51%$17M933.0K
2LABORATORY CORP AMER HLDGSCOM NEW5.65%$14M82.9K
3ZBHZIMMER BIOMET HLDGS INChistory →COM5.09%$13M109.6K
4WRIGHT MED GROUP N VORD SHS4.37%$11M372.0K
5RCMEURR1 RCM INChistory →COM4.12%$10M830.8K
6CICIGNA CORP NEWhistory →COM3.83%$10M61.6K
7PRAHPRA HEALTH SCIENCES INChistory →COM3.80%$10M97.2K
8IINUSDINTRICON CORPhistory →COM3.59%$9M389.8K
9OXFORD IMMUNOTEC GLOBAL PLCORD SHS3.41%$9M629.2K
10FLUIDIGM CORP DELNOTE 2.750% 2/03.31%$8M8.76M
11IRTCIRHYTHM TECHNOLOGIES INChistory →COM3.23%$8M103.4K
12SIENUSDSIENTRA INChistory →COM3.12%$8M1.29M
13HUMHUMANA INChistory →COM2.91%$7M27.8K
14EHCENCOMPASS HEALTH CORPhistory →COM2.87%$7M114.8K
15219AVEDRO INChistory →COM2.77%$7M357.9K
16ATRCATRICURE INChistory →COM2.58%$7M219.0K
17VCRAUSDVOCERA COMMUNICATIONS INChistory →COM2.55%$6M203.0K
18ABBVABBVIE INChistory →COM2.55%$6M89.0K
19ABGAMERISOURCEBERGEN CORPhistory →COM2.47%$6M73.5K
20XENTEURINTERSECT ENT INChistory →COM2.43%$6M270.6K
21HCAHCA HEALTHCARE INChistory →COM2.32%$6M43.6K
22SNYSANOFIhistory →SPONSORED ADR2.06%$5M120.6K
23AZNNASTRAZENECA PLChistory →SPONSORED ADR2.03%$5M124.9K
24EVOLENT HEALTH INCNOTE 2.000%12/01.96%$5M5.60M
25XRAYDENTSPLY SIRONA INChistory →COM1.91%$5M82.8K
26IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM1.67%$4M173.2K
27NVROEURNEVRO CORPhistory →COM1.62%$4M63.4K
28BMYBRISTOL MYERS SQUIBB COhistory →COM1.54%$4M86.3K
29LQDALIQUIDIA TECHNOLOGIES INChistory →COM1.48%$4M469.0K
30ACRSACLARIS THERAPEUTICS INChistory →COM1.41%$4M1.63M
31GW PHARMACEUTICALS PLCADS1.24%$3M18.2K
32IARTINTEGRA LIFESCIENCES HLDGS CCOM NEW0.94%$2M42.8K
33SGRYSURGERY PARTNERS INCCOM0.92%$2M287.7K
34NEON THERAPEUTICS INCCOM0.87%$2M465.6K
35OSMOTICA PHARMACEUTICALS PLCSHS0.77%$2M514.2K
36TRLDAVITA INCCOM0.72%$2M32.6K
372JQGRITSTONE ONCOLOGY INCCOM0.63%$2M143.8K
38SENSEONICS HLDGS INCNOTE 5.250% 2/00.61%$2M1.50M
39MRNSUSDMARINUS PHARMACEUTICALS INCCOM0.59%$2M362.2K
40SIBNSI BONE INCCOM0.52%$1M65.2K
41TNDMTANDEM DIABETES CARE INCCOM NEW0.50%$1M19.6K
42BUWABIO RAD LABS INCCL A0.46%$1M3.7K
43GNCAQGENOCEA BIOSCIENCES INCCOM NEW0.45%$1M289.7K
44MDMEDNAX INCCOM0.39%$994,00039.4K
45ATNMEURACTINIUM PHARMACEUTICALS INCCOM0.24%$610,0002.48M
46SRPTSAREPTA THERAPEUTICS INCCOM0.22%$570,0003.8K
47AFWALIGN TECHNOLOGY INCCOM0.21%$537,0002.0K
48GLYCEURGLYCOMIMETICS INCCOM0.20%$504,00042.3K
49TRANSLATE BIO INCCOM0.19%$490,00038.8K
50ADVMCHFADVERUM BIOTECHNOLOGIES INCCOM0.15%$379,00031.9K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.